

Special Issue

Molecular Determinants of Neurodegenerative Diseases

Message from the Guest Editor

Dear colleagues, Protein misfolding and the consequent aggregation and deposition of amyloid plaques are at the basis of severe and diffuse neurodegenerative dysfunctions. The pathways that lead a functional protein to a pathological state are characterized by a complex network of heterogeneous and transient species, making the investigation of these phenomena extremely challenging. This Special Issue is focused on scientific contributions highlighting the molecular factors that are critical in the onset or development of the disease (e.g., affecting the protein structure, modulating the aggregation kinetics and the aggregate morphology, inducing or abolishing toxicity, governing the prion-like spreading mechanism, etc.). Examples of such determinants are protein mutations, truncations or post-translational modifications, protein ligands, inhibitors of the aggregation pathway, molecules able to disassemble amyloid fibrils, etc. Original manuscripts, review articles, case reports, and commentaries related to this subject are all welcome.

- protein misfolding
- amyloid fibrils
- aggregation kinetics
- aggregate morphology
- aggregation inhibitor

Guest Editor

Dr. Carlo Santambrogio

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/100314

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).